Effect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenoma

  title={Effect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenoma},
  author={T. Miyoshi and F. Otsuka and M. Takeda and K. Inagaki and J. Suzuki and T. Ogura and I. Date and K. Hashimoto and H. Makino},
  journal={Journal of Endocrinological Investigation},
  • T. Miyoshi, F. Otsuka, +6 authors H. Makino
  • Published 2004
  • Medicine
  • Journal of Endocrinological Investigation
  • The present case involves a 47-yr-old woman with Cushing’s disease due to pituitary macroadenoma. The patient had suffered from hypertension and obesity for two yr. Her serum cortisol levels were moderately elevated throughout the observation period, and dexamethasone failed to suppress the cortisol secretion. Plasma ACTH levels were markedly high (>100 pg/ml) and did not respond to CRH provocation. Gel filtration analysis of the patient’s plasma detected the existence of big ACTH molecules… CONTINUE READING
    25 Citations
    An extra-adrenal abdominal pheochromocytoma causing ectopic ACTH syndrome.
    • 18
    • PDF
    Treatment of Cushing disease: overview and recent findings
    • 55
    • PDF
    Pituitary-directed medical treatment of Cushing’s disease
    • 1
    Remission with Cabergoline in Adolescent Boys with Cushing’s Disease
    • 3
    • PDF
    A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism.
    • 1
    • PDF
    Drugs in the medical treatment of Cushing's syndrome
    • 68
    • PDF
    The Treatment of Cushing's Disease.
    • 71
    • PDF


    ACTH silent adenoma shrinking under cabergoline.
    • 45
    • PDF
    Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
    • 80
    • PDF
    Management of Pituitary Tumors
    • 139
    Cabergoline in the treatment of acromegaly: a study in 64 patients.
    • 355
    • PDF
    Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    • 365
    • PDF